Pituitary metastasis from a renal cell carcinoma progressed after sorafenib treatment.

Author: Lin YANG ¹ ; Shi-Ying YU ; Guang-Yuan HU
Author Information

1. Huazhong Science and Technology University, Wuhan, Hubei, People's Republic of China.
Publication Type:Case Reports
MeSH: Antineoplastic Agents; therapeutic use; Carcinoma, Renal Cell; drug therapy; pathology; Humans; Kidney Neoplasms; drug therapy; pathology; Male; Middle Aged; Niacinamide; analogs & derivatives; therapeutic use; Phenylurea Compounds; therapeutic use; Pituitary Neoplasms; radiotherapy; secondary; Radiotherapy, Conformal
From:Chinese Journal of Cancer 2013;32(6):353-356
CountryChina
Language:English
Abstract: Pituitary metastasis from renal cell carcinoma is rare and has never been reported for renal cell carcinoma primarily treated with sorafenib. Herein, we present a case of an advanced clear-cell renal cell carcinoma in which pituitary metastasis progressed but extracerebral metastases showed partial response to sorafenib treatment.